LTR Pharma has gotten in bed with Shed, a young US direct-to-consumer tele-health company with 180,000 members. Shed will offer LTR Pharma's nasal spray ED drug via compounding pharmacies. The nasal spray will be branded as Roxus to preserve the Spontan brand for the future FDA approved launch.

While FDA approval is a few years away, the product can already be subscribed via a compounding pharmacy route because it is a reformulation of existing medicines. Over 1000 subscriptions have been sold under a similar arrangement in Australia.

Shed seems like a suitable partner, being young and looking for growth opportunities and having a compatible and non-competitive product suite. They currently sell GLP-1 weight-loss medication and various hair and longevity products. A promising and differentiated ED nasal spray could become a feature product for them.

The deal requires 150,000 units within the first year, allowing LTR Pharma the ability to see other people if Shed can't keep it up. No financial details were included but this is presumably a self-sustaining exercise to expose US ED customers to a superior product that they will want to try.